INTRODUCTION & OBJECTIVES: Biologic therapy is highly effective in the treament of psoriasis and psoriatic arthritis, but it’s associated to increased risk of infective complications. We present the case of a patient affected by severe psoriatic arthritis, recurrent urinary tract infections, cerebropathy due to perinatal anoxia, sensitive-motor polyneuropathy and congenital growth hormon deficiency. MATERIAL & METHODS: Due to the poor response to traditional therapies and the severity of articular affection, patient was treated with Ustekinumab 45mg sc under strict control by the infectious disease specialist. RESULTS: After 6 months of therapy we observed marked improvement of skin manifestation and articular symptoms, with no evidence of infectious complications. CONCLUSIONS: Biologic therapy with anti-IL12/23 agent should be considered as an effective and safe therapeutic option in treatment of psoriasis and psoriatic arthritis with important comorbidities.
Ustekinumab in the management of psoriatic arthritis in a patient affected by nervous system disorders and recurrent urinary tract infections / Potenza, Concetta; Proietti, Ilaria; Bernardini, Nicoletta; LA VIOLA, Giorgio; Nicolucci, Francesca; Tolino, Ersilia; Orsini, D.; Skroza, Nevena. - (2012). (Intervento presentato al convegno 21th EADV - SKIN IS VITAL tenutosi a PRAGUE nel 27-30 NOVEMBER 2012).
Ustekinumab in the management of psoriatic arthritis in a patient affected by nervous system disorders and recurrent urinary tract infections
POTENZA, Concetta;PROIETTI, ILARIA;BERNARDINI, NICOLETTA;LA VIOLA, GIORGIO;NICOLUCCI, FRANCESCA;TOLINO, ERSILIA;Orsini D.;SKROZA, Nevena
2012
Abstract
INTRODUCTION & OBJECTIVES: Biologic therapy is highly effective in the treament of psoriasis and psoriatic arthritis, but it’s associated to increased risk of infective complications. We present the case of a patient affected by severe psoriatic arthritis, recurrent urinary tract infections, cerebropathy due to perinatal anoxia, sensitive-motor polyneuropathy and congenital growth hormon deficiency. MATERIAL & METHODS: Due to the poor response to traditional therapies and the severity of articular affection, patient was treated with Ustekinumab 45mg sc under strict control by the infectious disease specialist. RESULTS: After 6 months of therapy we observed marked improvement of skin manifestation and articular symptoms, with no evidence of infectious complications. CONCLUSIONS: Biologic therapy with anti-IL12/23 agent should be considered as an effective and safe therapeutic option in treatment of psoriasis and psoriatic arthritis with important comorbidities.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
